Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

Summary

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

Timeline

Start

2003-04

Primary completion

—

Completion

2007-08

Outcome

Missed primary endpoint

paper imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression PMID 20007927 ↗

Publications

• Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.

Drugs

Indications